Literature DB >> 18306039

Immunoreactivity of antibodies against transglutaminase-deamidated gliadins in adult celiac disease.

Maria Letizia Falini1, Luca Elli, Rosita Caramanico, Maria Teresa Bardella, Claudia Terrani, Leda Roncoroni, Luisa Doneda, Fabio Forlani.   

Abstract

BACKGROUND: The significance of the presence of anti-gliadin antibodies in patients affected by celiac disease is still unclear. It is hypothesized that gliadin deamidation, catalysed by transglutaminase, plays a role in favoring the antigen presentation. AIM: To determine the immunoreactivity of anti-gliadin antibodies from untreated celiac patients to transglutaminase deamidated gliadins.
MATERIALS AND METHODS: Gliadins from wheat flour underwent enzymatic digestion and were deamidated or cysteamine-transamidated by transglutaminase. Immunoreactivity of anti-gliadin antibodies from untreated adult celiac patients sera was evaluated by means of a competitive enzyme-linked immunosorbent assay (ELISA) method.
RESULTS: Gliadin deamidation increased antibodies immunoreactivity from 25% to 50% while cysteamine incorporation into the gliadin peptides resulted in an immunoreactivity decrease.
CONCLUSIONS: Increased immunoreactivity of transglutaminase deamidated gliadins tested with anti-gliadin antibodies from untreated adult celiac patients supports the hypothesis of a pivotal role of gliadin deamidation in the pathomechanism of celiac disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306039     DOI: 10.1007/s10620-007-0191-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Inflammation does not decrease intraluminal pH in chronic inflammatory bowel disease.

Authors:  K Ewe; S Schwartz; S Petersen; A G Press
Journal:  Dig Dis Sci       Date:  1999-07       Impact factor: 3.199

2.  B cell epitopes of gliadin.

Authors:  A A Osman; T Günnel; A Dietl; H H Uhlig; M Amin; B Fleckenstein; T Richter; T Mothes
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Susceptibility to transglutaminase of gliadin peptides predicted by a mass spectrometry-based assay.

Authors:  Gianfranco Mamone; Pasquale Ferranti; Dominique Melck; Filomena Tafuro; Luigi Longobardo; Lina Chianese; Francesco Addeo
Journal:  FEBS Lett       Date:  2004-03-26       Impact factor: 4.124

Review 4.  Recent advances in coeliac disease.

Authors:  D A van Heel; J West
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

5.  Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up.

Authors:  Umberto Volta; Alessandro Granito; Erica Fiorini; Claudia Parisi; Maria Piscaglia; Georgios Pappas; Paolo Muratori; Francesco B Bianchi
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

6.  Natural history of antibodies to deamidated gliadin peptides and transglutaminase in early childhood celiac disease.

Authors:  Edwin Liu; Marcella Li; Lisa Emery; Iman Taki; Kathy Barriga; Claudio Tiberti; George S Eisenbarth; Marian J Rewers; Edward J Hoffenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-09       Impact factor: 2.839

Review 7.  Relation between gliadin structure and coeliac toxicity.

Authors:  H Wieser
Journal:  Acta Paediatr Suppl       Date:  1996-05

Review 8.  Current concepts of celiac disease pathogenesis.

Authors:  D Schuppan
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

9.  Antibody responses to deamidated gliadin peptide show high specificity and parallel antibodies to tissue transglutaminase in developing coeliac disease.

Authors:  M Ankelo; V Kleimola; S Simell; O Simell; M Knip; E Jokisalo; M Tarkia; A Westerlund; Q He; M Viander; J Ilonen; A E Hinkkanen
Journal:  Clin Exp Immunol       Date:  2007-09-04       Impact factor: 4.330

10.  In vitro cytotoxic effect of bread wheat gliadin on the LoVo human adenocarcinoma cell line.

Authors:  E Dolfini; L Elli; T Dasdia; B Bufardeci; M P Colleoni; B Costa; I Floriani; M L Falini; N Guerrieri; F Forlani; M T Bardella
Journal:  Toxicol In Vitro       Date:  2002-08       Impact factor: 3.500

View more
  3 in total

1.  Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis.

Authors:  Aaron Lerner; Torsten Matthias
Journal:  Nutr Rev       Date:  2015-06-16       Impact factor: 7.110

2.  Application of Deamidated Gliadin Antibodies in the Follow-Up of Treated Celiac Disease.

Authors:  Luc de Chaisemartin; Tchao Meatchi; Georgia Malamut; Fahima Fernani-Oukil; Frédérique Hosking; Dorothée Rault; Fabienne Bellery; Christophe Cellier; Marie-Agnès Dragon-Durey
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240

Review 3.  Processed Food Additive Microbial Transglutaminase and Its Cross-Linked Gliadin Complexes Are Potential Public Health Concerns in Celiac Disease.

Authors:  Aaron Lerner; Torsten Matthias
Journal:  Int J Mol Sci       Date:  2020-02-08       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.